KR | EN

News

Check out the latest news and media coverage from SML Biopharm.

Featured

Featured News

Cha Vaccine Institute and SML Biopharm to Jointly Develop mRNA-Based Vaccines and Therapeutics
September 9, 2025

Cha Vaccine Institute and SML Biopharm to Jointly Develop mRNA-Based Vaccines and Therapeutics

Cha Vaccine Research Institute and SML BioPharm have signed an MOU for the joint development of mRNA-based vaccines and therapeutics, aiming to establish new pipelines, including cancer vaccines, and an efficient development model.

All News

Cha Vaccine Institute and SML Biopharm to Jointly Develop mRNA-Based Vaccines and Therapeutics
2025.09.09

Cha Vaccine Institute and SML Biopharm to Jointly Develop mRNA-Based Vaccines and Therapeutics
“My-Own Cancer Vaccine” Becomes Reality…Catholic University of Korea Develops Personalized mRNA Cancer Vaccine
2025.07.31

“My-Own Cancer Vaccine” Becomes Reality…Catholic University of Korea Develops Personalized mRNA Cancer Vaccine
Securing advanced mRNA technology to bolster vaccine sovereignty
2025.07.21

Securing advanced mRNA technology to bolster vaccine sovereignty
SML Biopharm Signs MOU with France's Affilogic to Develop mRNA-LNP-Based Targeted Therapeutics
2025.05.08

SML Biopharm Signs MOU with France's Affilogic to Develop mRNA-LNP-Based Targeted Therapeutics
South Korea's SML Biopharm Signs MOU with France's Affilogic
2025.05.08

South Korea's SML Biopharm Signs MOU with France's Affilogic
North Chungcheong Province launches Biopharmaceutical Materials, Parts and Equipment Regulatory Improvement Support Program (SML Biopharm selected)
2025.05.01

North Chungcheong Province launches Biopharmaceutical Materials, Parts and Equipment Regulatory Improvement Support Program (SML Biopharm selected)
Professor Nam Jae‑hwan’s research team at The Catholic University of Korea develops an mRNA‑based therapeutic for the “killer tick virus”
2025.04.16

Professor Nam Jae‑hwan’s research team at The Catholic University of Korea develops an mRNA‑based therapeutic for the “killer tick virus”
SML Biopharm Presents Advances in mRNA-Based Antibody Therapeutics at European mRNA Conference
2025.02.03

SML Biopharm Presents Advances in mRNA-Based Antibody Therapeutics at European mRNA Conference
Prof. Nam Jae-hwan of Catholic University Selected among Top 100 National R&D Achievements
2025.01.24

Prof. Nam Jae-hwan of Catholic University Selected among Top 100 National R&D Achievements
Theragen Bio Signs MOU with SML Biopharm to Develop Cancer Vaccine
2024.12.20

Theragen Bio Signs MOU with SML Biopharm to Develop Cancer Vaccine
SML Biopharm Signs MOU with CATUG to Collaborate on mRNA Technology Development
2024.12.06

SML Biopharm Signs MOU with CATUG to Collaborate on mRNA Technology Development
Yubiologics launches collaboration to develop mRNA vaccines against novel and variant infectious diseases
2024.12.05

Yubiologics launches collaboration to develop mRNA vaccines against novel and variant infectious diseases